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Background: Recent work has shown that the chaperone resistant to inhibitors of acetylcholinesterase (RIC-3) is critical
for the folding, maturation and functional expression of a variety of neuronal nicotinic acetylcholine receptors. α7
nicotinic receptors can only assemble and functionally express in select lines of cells, provided that RIC-3 is present. In
contrast, α4β2 nicotinic receptors can functionally express in many cell lines even without the presence of RIC-3.
Depending on the cell line, RIC-3 has differential effects on α4β2 receptor function – enhancement in mammalian cells
but inhibition in Xenopus oocytes. Other differences between the two receptor types include nicotine-induced
upregulation. When expressed in cell lines, α4β2 receptors readily and robustly upregulate with chronic nicotine
exposure. However, α7 nicotinic receptors appear more resistant and require higher concentrations of nicotine to
induce upregulation. Could the coexpression of RIC-3 modulate the extent of nicotine-induced upregulation not only
for α7 receptors but also α4β2 receptors? We compared and contrasted the effects of RIC-3 on assembly, trafficking,
protein expression and nicotine-induced upregulation on both α7 and α4β2 receptors using fluorescent protein
tagged nicotinic receptors and Förster resonance energy transfer (FRET) microscopy imaging.
Results: RIC-3 increases assembly and cell surface trafficking of α7 receptors but does not alter α7 protein expression in
transfected HEK293T cells. In contrast, RIC-3 does not affect assembly of α4β2 receptors but increases α4 and β2
subunit protein expression. Acute nicotine (30 min exposure) was sufficient to upregulate FRET between α4 and β2
subunits. Surprisingly, when RIC-3 was coexpressed with α4β2 receptors nicotine-induced upregulation was prevented.
α7 receptors did not upregulate with acute nicotine in the presence or absence of RIC-3.
Conclusions: These results provide interesting novel data that RIC-3 differentially regulates assembly and expression of
different nicotinic receptor subunits. These results also show that nicotine-mediated upregulation of α4β2 receptors
can be dynamically regulated by the presence of the chaperone, RIC-3. This could explain a novel mechanism why
high affinity α4β2 receptors are upregulated in specific neuronal subtypes in the brain and not others.
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Nicotinic acetylcholine receptors (nAChRs) are penta-
meric ligand-gated cation channels that are activated by
the endogenous agonist acetylcholine and the pharmaco-
logical agent of tobacco, nicotine. There are 17 different
nicotinic subunits found in vertebrates, 12 of which are
the neuronal variety (α2-α10 and β2-β4). The most* Correspondence: raad@uvic.ca
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α4β2* receptor subtype (* denotes that the receptor may
comprise distinct additional subunits) and is the major
receptor subtype in the brain with high affinity to nico-
tine. This receptor upregulates with chronic nicotine ex-
posure in a variety of in vitro and in vivo models
including cultured cell lines[1-4], rodents’ brains [5-7]
and the brains of smokers [8]. However, the mechanism
of nicotinic receptor upregulation is not clearly delin-
eated although many mechanisms have been proposed
[1-4,9,10]. The homomeric α7 receptor is the next most
prevalent nAChR in the CNS with low sensitivity to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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induced upregulation, though α7 receptor upregulation
can be attained with higher concentrations of nicotine in
cell culture [11-13] and in more limited brain regions of
receptor upregulation in rodents with in vivo nicotine
administration [14]. Furthermore, until recently unlike
α4β2 receptors, which can be functionally expressed in
many cell lines, α7 can only be functionally expressed in
select cell lines [15-17].
A breakthrough in the field occurred when the ric-3
gene was discovered in mutant Caenorhabditis elegans,
which were resistant to inhibitors of acetylcholinesterase
[18,19]. The gene product, RIC-3, which is a transmem-
brane protein with cytoplasmic coiled-coil domains [20],
enhances functional expression of nicotinic receptors,
5-HT3 receptors but not GABA nor glutamate ligand-
gated ion channels [17,19,21-23]. RIC-3 is an obligatory
chaperone protein for maturation, assembly and surface
trafficking of α7 receptors [20-22]. It was also reported
that RIC-3 can interact with the heteromeric α4β2 re-
ceptors [17,19]. However, the role of RIC-3 in influen-
cing α4β2 receptor functional expression appears more
complex due to conflicting reports. While some studies
showed that RIC-3 can inhibit function of α4β2 recep-
tors when coexpressed in Xenopus oocytes [24], another
showed that in mammalian cells RIC-3 can enhance the
function of α4β2 nAChRs [17].
In the present study, we compared and contrasted the
effects of RIC-3 in modulating assembly, trafficking and
protein expression between α4β2 and α7 nAChRs in
HEK293T mammalian cells, using nicotinic receptors
tagged with fluorescent proteins. We also examined
whether the presence of RIC-3 may alter nicotine-induced
receptor upregulation for α4β2 nAChRs and whether the
coexpression of RIC-3 can facilitate nicotine-induced
upregulation for α7 receptors, which are relatively resist-
ant to upregulation as compared to α4β2. We found that
RIC-3 increased α7 receptor assembly and trafficking to
the surface but did not alter α7 protein expression. In con-
trast, RIC-3 did not affect α4β2 nAChR assembly but in-
creased α4 and β2 protein expression. Interestingly, acute
application of nicotine for 30 min was sufficient to
upregulate FRET between α4 and β2 subunits, while RIC-
3 prevented nicotine-mediated increased FRET between
α4 and β2. Nicotine exposure for 30 min was incapable of
upregulating assembly of α7 receptors, whether in the
presence or absence of RIC-3.
Methods
cDNA constructs
Mouse α7, α4 and β2 nAChR cDNAs were kindly pro-
vided by Jerry Stitzel (University of Michigan, Ann
Arbor, MI). Human RIC-3 cDNA was provided by Neil
Millar (The University College London, UK [17]).William Green kindly provided CFP-RIC-3, in which
cyan fluorescent protein (CFP) is fused to the N
terminus of RIC-3 (University of Chicago [22]). Venus
fluorescent protein cDNA was provided by Atsushi
Miyawaki (Riken Brain Science Institute, Tokyo, Japan)
[25] and Cerulean fluorescent protein cDNA was pro-
vided by David Piston (Vanderbilt University Medical
Center, Nashville, Tennessee)[26]. The construction of
α4CFP, α4YFP (yellow fluorescent protein), β2CFP and
β2YFP nAChR subunits, with the fluorescent protein
inserted into the M3-M4 cytoplasmic loop, has been
reported previously and they function normally in every
respect [1,27,28].
Fluorescently tagged α7 nAChR subunits were pro-
duced by inserting Cerulean or Venus cDNA into the
M3-M4 cytoplasmic loop of α7. A BstEII restriction site
was introduced into the M3-M4 intracellular loop of α7
using site directed mutagenesis (QuikChange XL Site-
Directed Mutagenesis Kit, cat# 200521, Stratagene) using
the forward primer 50-CT CTA CAT TGG CTT CCG
AGG CGG TCA CCT CCT GGA GGG CAT GCA
CTG TG -30 and the reverse primer 50-CA CAG TGC
ATG CCC TCC AGG AGG TGA CCG CCT CGG AAG
CCA ATG TAG AG-30. Cerulean was PCR amplified
(Expand High Fidelity Plus PCR System, cat# 03 300 242
001, Roche) with the forward primer 50 - T TTT CGG
TCA CCTT GAG CAG AAG CTG ATC TCA GAG
GAG GAT CTG GTG AGC AAG GGC GAG GAG
CTG TTC - 30 and the reverse primer 50 - A AAA CAG
CTT CTG CTC CAT ATC ACC TGA TCG CTG CGG
TGA CC CTT GTA CAG CTC GTC CAT GCC GAG -
30. This introduced flanking BstEII restriction sites and
an upstream c-myc epitope tag. Similarly, Venus was
PCR amplified with the forward primer 50 - T TTT CGG
TCA CCTT TAT CCT TAT GAC GTC CCA GAC TAC
GCC GTG AGC AAG GGC GAG GAG CTG TTC - 30
and the reverse primer 50 - A AAA GTG CAC ACG
GTA AGG ATG GTA GTC TCA CGG TGA CC CTT
GTA CAG CTC GTC CAT GCC GAG - 30 introducing
flanking BstEII restriction sites and an upstream
hemagglutinin epitope tag. We performed whole-cell
patch-clamp recordings on HEK293T cells transfected
with α7-Venus and wildtype α7 cDNA. α7-Venus recep-
tors function normally. They have similar maximal peak
current amplitudes and dose–response relations to ACh
as compared to wildtype α7 receptors (data not shown).
Culture and transfection of HEK293T cells
Human embryonic kidney HEK293T cells (ATCC) were
maintained in Dulbecco’s Modified Eagle medium
(DMEM), supplemented with 10% fetal calf serum, 2 mM
L-glutamine, 100 U/ml penicillin and 100 μg/ml strepto-
mycin. Glass coverslip bottom dishes (35 mm, cat# P35G-
0-14-C, MatTek Corporation) were coated for 2 hrs with
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maintained in a 5% CO2 incubator at 37°C. Cells were
grown to 40–50% confluency and then transiently
transfected with Fugene Transfection Reagent (cat #
PRE2311, Promega). For each dish, equimolar masses
(0.4 - 0.6 μg) of α7-Venus and α7-Cerulean or α4CFP and
β2YFP cDNA were mixed in 200 μl of incomplete DMEM
medium (containing 2 mM L-glutamate but lacking serum
and antibiotics) with 3 μl of Fugene transfection reagent
(cat # PRE2311, Promega) and transfection was performed
according to the manufacturer’s protocol. In experiments
studying the effects of RIC-3, RIC-3 was also added to the
transfection mixture with incomplete DMEM medium at
0.02:1, 0.1:1, 1:1, or 5:1 molar ratios of RIC-3 to nAChR
plasmid cDNA.
Spectral confocal imaging
Cultured HEK293T cells were imaged 2 days post-
transfection in extracellular solution (ECS) maintained at
30°C using a heated stage (cat# QE-1, Warner Instruments)
connected to a temperature controller (cat# TC-344B,
Warner Instruments). ECS contained in mM 150 NaCl,
4 KCl, 2 MgCl2, 2 CaCl2, 10 HEPES, 10 glucose and 2
ascorbic acid (pH 7.4). For experiments that required nico-
tine treatment, cultured cells were incubated at 37°C for
30 min with nicotine at one of various concentrations (0.1,
1 or 10 μM) and then washed three times in warmed ECS
prior to imaging. Imaging was performed on a Nikon C1si
laser scanning spectral confocal inverted microscope
(Eclipse Ti-E, Nikon) using a 60X oil CFI Plan Apo VC
objective (1.40 N.A., 0.13mm working distance). For each
cell, a lambda stack of X-Y images was collected simultan-
eously with one laser sweep and onto an array of 32
photomultiplier tubes over a wavelength range from 466 –
626 nm at 5 nm separation. Images were acquired at 512 ×
512 pixels at 25 × 25 μm. The pixel dwell time was set at
10 μsec and the pinhole was set to large (100 μm diameter).
Pixel based sensitized acceptor emission FRET microscopy
Pixel-by-pixel based sensitized acceptor FRET microscopy
was performed according to previous reports [28-32]. It
was necessary to correct for spectral bleed through (SBT)
arising from the significant overlap of Venus/Cerulean or
CFP/YFP excitation and emission spectra. To detect bleed
through due to emission of the donor fluorophore (Ceru-
lean or CFP) signal into the acceptor channel (Venus or
YFP) (SBTdonor), cells expressing donor fluorophore only
(CFP or Cerulean) were imaged. The donor fluorophore
was excited with the 457 nm line of an argon laser at 5%
maximum intensity, and emission intensities were col-
lected at both the emission peak channel of Cerulean/CFP
(478 nm) and the emission peak channel of Venus/YFP
(528 nm). Similarly, to detect bleed through due to partial
excitation of the acceptor when exciting the donor(SBTacceptor), cells expressing acceptor fluorophore only
(Venus or YFP) were imaged. The acceptor fluorophore
(Venus or YFP) was excited at both the 457 nm line at 5%
maximal intensity) and the 514 nm line (0.5% maximal in-
tensity) of the argon laser, and emission was detected at
the 528 nm channel. Bleed through ratios were calculated
to be 0.15 for SBTacceptor and 0.49 for SBTdonor. The spec-
tral gain setting was set to a value so that there were no
saturated pixels.
Sensitized emission FRET efficiencies were then deter-
mined for cells expressing both donor and acceptor. The ac-
ceptor fluorphore (YFP/Venus) was excited with the 514 nm
line at 0.5% maximal intensity, and acceptor emission inten-
sity was measured at the 528 nm channel (Iacceptor).
Then the donor fluorophore (CFP/Cerulean) was ex-
cited with the 457 nm line at 5% maximal intensity, and
emission was measured at the 478 nm channel for meas-
urement of the donor fluorescence intensity (Idonor), and
at the 528 nm channel for measurement of sensitized ac-
ceptor emission of FRET fluorescence (IFRET). Image ana-
lysis of FRET efficiencies was performed with ImageJ
v1.43r software (http://rsbweb.nih.gov/ij/) using either the
PixFRET plugin [31] to determine pixel based FRET effi-
ciencies or using mean pixel values within a region of
interest (ROI) for ROI based FRET efficiency calculations
but using the same calculations as that of the PixFRET
plugin. Nikon ics/ids confocal image files were opened
using the ImageJ plugin, “loci_tools.jar” (http://www.loci.
wisc.edu/bio-formats/imagej). Net FRET (nFRET) was cal-
culated according to equation (1), using the bleed through
ratios reported above.





For all cells, the background signal was subtracted and in-
tensity measurements were collected from regions of interest
(ROI) on the cell expressing an even and unsaturated fluor-
escence emission signal. FRET efficiencies were calculated by
the ImageJ 1.43r software, according to equation (2),
E ¼ 1– IDA=IDð Þ ð2Þ
where E represents FRET efficiency, IDA represents emis-
sion intensity of the donor in the presence of acceptor
(Idonor, equation (1)), and ID represents emission intensity
of the donor alone [33]. ID was estimated by the software
as the experimental donor emission intensity in the pres-
ence of the acceptor IDA or Idonor added to the emission
intensity of the sensitized acceptor emission channel
(nFRET ), as shown in equation (3).
E ¼ 1– IDA= IDA þ nFRETð Þð Þ ð3Þ
The PixFRET plugin calculated FRET efficiency does
not correct the nFRET value for the difference in relative
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ive extinction coefficients and quantum efficiencies. A
set of control experiments are shown in Figure 1K valid-
ating the FRET measurements for relative comparisons
of FRET changes.
Labelling and imaging of α-bungarotoxin and epitope tag
antibody binding
For surface labelling of α-bungarorotoxin sites, cells were
fixed in 4% paraformaldehyde (PFA) dissolved in PBS for
10 to 30 min at room temperature. Cells were then incu-
bated in 2 μg/ml Alexa Fluor 647 α-bungarotoxin (Fl-Bgt)
(cat# B35450, Invitrogen) diluted in PBS for 30 min. For
total α-bungarotoxin labelling (cytoplasmic and surface),
cultured cells were fixed in 4% PFA for 30 min at room
temperature followed by 5 min incubation of 0.25%
Triton-X to permeabilize the membrane, and then 2 μg/
ml Fl-Bgt incubation for 30 min. Between each step, cells
were washed three times in PBS for 5 min intervals.
α4YFP and β2YFP subunits each contained a hemagglu-
tinin (HA) epitope tag in addition to the fluorescent pro-
tein. For anti-HA tag antibody (rabbit polyclonal, cat#
ab9110, abcam) labelling of α4YFP or β2YFP total nico-
tinic receptors, cells were fixed in 4% PFA in PBS for
10 min followed by 5 min incubation of 0.25% Triton-X,
30 min incubation of 10% donkey serum, 1 hr incubation
of anti-HA (1:100 diluted in 3% donkey serum in PBS)
and finally 1 hr incubation of CY5 conjugated donkey
anti-rabbit IgG secondary antibody (1:200 diluted in 3%
donkey serum in PBS). Cells were washed three times for
5 min in PBS between each step.
Measurement of α7-Cerulean/Venus or α4CFP β2YFP
fluorescence was performed as previously reported for the
sensitized emission experiments. Fl-Bgt was excited with a
638 nm diode laser line at 15% maximal intensity, and
emission was measured at the emission peak channel
(665 nm) following spectral unmixing with a 525 nm sig-
nal as a reference. CY5 was excited with a 638 nm diode
laser line at 3% maximal intensity and emission measured
following spectral unmixing. Images were analyzed for
mean signal intensity using ImageJ v1.43r software.
Statistical analysis
Values are reported as mean ± standard error. Significant
difference (p < 0.05) between more than two groups of
data meeting assumptions of normality and homogeneity
of variances was analyzed by a one-way ANOVA followed
by post hoc multiple pairwise analysis using a Tukey’s
HSD test. If the data did not meet these assumptions a
Kruskal-Wallis rank sum test was performed followed by
pairwise comparisons using Wilcoxon rank sum tests. Sig-
nificant difference (p < 0.05) between two groups of data
was determined using a t-test for continuous data meeting
parametric assumptions of equal variances and normality.Otherwise, a Wilcoxon rank sum test was performed for
nonparametric data. We also performed the Welch two
sample t-test for a comparison of two groups of data
which were normally distributed but failed the equal vari-
ance test. For analysis of data with two independent vari-
ables, a two-way ANOVA was performed, followed by
post hoc multiple pairwise analysis using a Tukey’s HSD
test. All statistical analyses were performed using the R
statistical computing language [34].
Results
RIC-3 mediates assembly between α7 subunits
FRET is a spectroscopic technique that can determine
whether two fluorescently tagged molecules interact
since the distance separating the donor and acceptor
fluorophores must be within 100 Å for energy transfer to
occur. We have previously used FRET as a spectroscopic
technique to assay receptor assembly between fluores-
cently tagged α4 and β2 nAChR subunits in living cells
[1,27]. Based on previous literature that RIC-3 is necessary
for functional expression of α7 nAChRs, we performed
FRET experiments of fluorescently labelled α7 nAChR
subunits in the absence and various concentrations of
RIC-3 to examine whether α7 subunits are assembled in
the absence of RIC-3 and to what extent RIC-3 can
stimulate the assembly of α7 nicotinic receptors.
To determine the influence of RIC-3 on α7 nAChR as-
sembly, α7 subunits tagged with either Cerulean or Venus
fluorescent proteins were cotransfected with RIC-3 at 0:1,
0.02:1, 0.1:1, 1:1 and 5:1 transfection ratios (RIC-3 to α7
cDNA), and sensitized FRET imaging was performed to
determine the absolute FRET efficiency between subunits.
Increasing expression of the RIC-3 chaperone with fluo-
rescently tagged α7 subunits led to a significant and steady
increase (p < 0.0001, Kruskal-Wallis rank sum test) in
FRET efficiency (Figure 1). This increase was significant at
0.1:1 (p = 0.0004, Wilcoxon rank sum test post-hoc ana-
lysis) and at 1:1 (p = 0.0001, Wilcoxon rank sum test post-
hoc analysis) transfection ratios of RIC-3 to α7 cDNA,
and peaked at the 1:1 transfection ratio. The highest level
of RIC-3 expression (5:1) reduced the FRET efficiency
toward control value. Figure 1 shows the relative fluor-
escence from the donor (α7-Cerulean), the acceptor
(α7-Venus) and pixel based FRET efficiency image in the
control (no RIC-3), 1:1, and 5:1 molar ratios (RIC-3 to α7
cDNA). Consistent with the summary data presented in
Figure 1J, the FRET signal was higher when RIC-3 was
cotransfected at a 1:1 ratio than in cells that lacked
RIC-3 or expressed RIC-3 at a 5:1 ratio to α7. There-
fore, increasing doses of RIC-3 progressively increases
assembly of α7 nAChRs peaking at a 1:1 ratio of RIC-3:α7
subunits. However, when RIC-3 outnumbers α7 then
assembly of α7 nicotinic receptors decreases to baseline
values similar to that found in the absence of RIC-3.
Figure 1 Changes in FRET efficiency between fluorescent α7 subunits upon co-transfection with RIC-3. Pixel based FRET was used to
monitor assembly between α7-Venus and α7-Cerulean nAChR subunits. RIC-3 concentration was varied as molar ratio to total α7 plasmid: 0:1
(negative control), 0.02:1, 0.1:1, 1:1, and 5:1. Confocal images of transfected HEK293T cells showing α7-Cerulean (A, D, G), α7-Venus (B, E, H) and
FRET efficiency (C, F, I) expression. FRET efficiency was higher in cells expressing RIC-3 at a 1:1 ratio to α7 (F) than cells not expressing RIC-3 (C) or
cells expressing RIC-3 at a 5:1 ratio to α7 (I). (J) Summary plot showing that FRET efficiencies increased significantly (p < 0.0001, Kruskal-Wallis rank
sum test) with increasing concentrations of RIC-3 relative to α7 but went to baseline at 5:1 ratio. There was a significant increase of FRET
efficiency at 0.1:1 RIC-3 to α7 (p = 0.0004, Wilcoxon rank sum test) as compared to no RIC-3 cells and at 1:1 RIC-3 relative to α7 (p < 0.0001,
Wilcoxon rank sum test). Numbers inside the plot represent the number of cells analyzed. (K) Control experiments validating the FRET
measurements. α4YFP β2CFP shows significantly greater FRET efficiency than α4CFP β2YFP. This is expected because the transfection ratio favours
an (α4)3(β2)2 stoichiometry [1] and the combination with the more acceptors (YFP) theoretically would have greater FRET efficiency. GYFP GCFP
(GluClβ-YFP GluClα-CFP) are heteromeric glutamate-gated chloride channels found in invertebrates and show high FRET. Although they are
members of the cys-loop family of receptors, they are not expected to assemble with any of the nicotinic receptors. Our negative control
experiment, α4YFP GCFP (GluClα-CFP) shows very little FRET. A positive control experiment with RIC-3 and α7V α7C (α7-Venus α7-Cerulean)
showing significant levels of FRET. Numbers inside the bars represent the number of cells analyzed.
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nAChRs
Several studies have proposed that RIC-3 promotes sur-
face trafficking of α7 receptors [17,22,23,35]. α-Bungaro-
toxin is a slowly reversible competitive antagonist that
binds at the interface of adjacent α7 nAChR subunits
and therefore can indicate the degree of receptor assem-
bly. Alexa Fluor 637 α-bungarotoxin (Fl-Bgt) labelling in
nonpermeabilized and permeablized conditions was
performed to accurately quantify assembled α7 nAChRs
both at the surface and the total cellular pool of recep-
tors, respectively. Confocal images of control cells and
cells coexpressing RIC-3 at the 1:1 ratio are shown in
Figure 2. The Fl-Bgt signal was almost undetectable in
the absence of chaperone, and markedly increased in in-
tensity at a 1:1 transfection ratio. In nonpermeabilized
conditions with RIC-3 coexpressed at 1:1, Fl-Bgt label-
ling of surface receptors displayed a ring-like labelling
pattern on the perimeter of the cell. Under perme-
abilized conditions the total Fl-Bgt labelling appeared
evenly throughout the cytoplasm of the cell, with noFigure 2 RIC-3 increases whole cell and cell surface expression of α-B
binding assays using Alexa 648 α-Bgt (Fl-Bgt) and performed under nonpe
RIC-3 (1:1 to α7), and permeabilizing conditions (I, J, K, L) without RIC-3 an
α7-Venus, Fl-Bgt binding sites and the merged α7-Venus / Fl-Bgt images ar
intracellular α-Bgt binding sites.obvious outline of Fl-Bgt labelling near the cell surface.
This indicates that although surface receptors exist,
there is a large cytoplasmic pool of receptors. In general,
whole cellular levels of assembled α7 nAChRs were
higher than levels of surface receptors (Figure 3). The
total cellular number of Fl-Bgt binding sites increased
steadily with increasing levels of RIC-3 (p < 0.0001,
Kruskal-Wallis rank sum test), with the highest expres-
sion at a 5:1 transfection ratio of RIC-3 to α7 cDNA (4.6
fold increase vs no RIC-3) (Figure 3). In contrast, surface
Fl-Bgt fluorescence intensity steadily increased (p = 0.0003,
Kruskal-Wallis rank sum test) to a peak of 24 fold at a 1:1
ratio to α7 and decreased closer to baseline at a 5:1 ratio,
which paralleled our FRET data (Figure 3). These results
show that RIC-3 enhances assembly and forward trafficking
of α7 nAChRs to the cell surface.
RIC-3 does not increase α7 subunit protein expression
It is possible that the increase in total α-Bgt binding sites
with RIC-3 coexpression was not caused by upregulated
assembly alone but also by changes in the protein levelsgt binding sites. Spectral confocal microscopy images of α-Bgt
rmeabilizing conditions (A, B, C, D) without RIC-3, or (E, F, G, H) with
d (M, N, O, P) with RIC-3 (1:1 to α7). Emission signals from α7-Cerulean,
e shown for each corresponding cell. RIC-3 increases surface and
Figure 3 RIC-3 increases whole cell Fl-Bgt labelling and surface trafficking of α7 receptors but does not alter protein levels. Increasing
concentrations of RIC-3 progressively augmented total Fl-Bgt binding under cell permeabilizing conditions (A, B). Fl-Bgt binding of surface α7
receptors also increased with RIC-3 but peaked at 1:1 RIC-3 to α7 and diminished at a 5:1 ratio (A, B). Total (A) and fold-change (B) of Fl-Bgt
binding is shown. The surface and whole cell number of Fl-Bgt binding sites was quantified by measuring the integrated density of fluorescence
intensities of Alexa 648-tagged α-bungarotoxin around the outer surface of each cell or within the cell, for non-permeabilizing and
permeabilizing conditions, respectively. Significant difference levels comparing groups of RIC-3 coexpressing cells relative to no RIC-3 controls: *
p < 0.05, ** p < 0.01, *** p < 0.001 Wilcoxon rank sum test post-hoc pair wise analysis. The number of cells analyzed for total receptor labelling in
(A, B) are 0:1 (negative control, n = 14), 0.02:1 (n = 13), 0.1:1 (n = 14), 1:1 (n = 18), and 5:1 (n = 15). The number of cells analyzed for surface
receptor labelling in (A, B) are 0:1 (n = 6), 0.02:1 (n = 8), 0.1:1 (n = 8), 1:1 (n = 11), and 5:1 (n = 11). (C, D) Mean emission intensity of the α7-Venus
and α7-Cerulean fluorophores per HEK293T cell were determined at various concentrations of RIC-3. There was no significant change in either
α7-Venus or α7-Cerulean fluorescent protein levels with various amounts of RIC-3 co-expressed inside the cells (p = 0.6, one-way ANOVAs; and
p = 0.2, Kruskal-Wallis rank sum test, respectively).
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the increase in total Fl-Bgt binding sites was caused by
an upregulated amount of α7 nAChR subunit protein.
To address this, the emission signals generated by α7-
Cerulean and α7-Venus were measured with various
levels of RIC-3 to detect any effect of the chaperone on
subunit expression levels. There were no significant
changes in fluorescence intensity of both α7-Venus
(p = 0.7, one-way ANOVA) and α7-Cerulean (p = 0.2,
Kruskal-Wallis rank sum test), indicating that similar
amounts of α7 subunits were expressed regardless of the
level of expression of RIC-3. Therefore, RIC-3 stimulates
α7 receptor assembly but has no effect on protein levels
of individual α7 nAChR subunits.
RIC-3 does not increase assembly between α4 and β2, but
increases α4 and β2 subunit protein expression
Previous work has suggested that RIC-3 can interact
with a variety of receptor subunits in addition to α7
nAChRs [17,22,23,35]. Therefore, it is important todetermine whether RIC-3 specifically increases α7
nAChR assembly or whether it can also enhance assem-
bly of α4β2 receptors, the major heteromeric nAChRs in
the CNS. Using FRET measurements to quantify recep-
tor assembly, we found that varying the amounts of
RIC-3 did not significantly change the FRET efficiencies
between α4CFP and β2YFP nicotinic subunits up to a
1:1 ratio of RIC-3 to α4CFP β2YFP cDNA (p = 0.08, one-
way ANOVA) (Figure 4). Thus, RIC-3 has no influence
on the assembly of α4β2 receptors, as is the case with
α7. However, at a high RIC-3 concentration (5:1, RIC-3 :
α4CFP β2YFP) there was decreased FRET between
α4CFP and β2YFP, indicating fewer assembled receptors.
This was similar to the effect of decreased FRET be-
tween α7-Venus and α7-Cerulean with high RIC-3 ex-
pression at 5:1.
Because RIC-3 at the moderate to low concentrations
had no effect on assembly of α4β2 receptors, we
expected that there would be no change in α4 and β2
subunit protein levels. To our surprise, we found that
Figure 4 Effect of various concentrations of RIC-3 on FRET efficiencies between α4CFP and β2YFP subunits and protein expression
levels of α4CFP and β2YFP subunits. Equimolar amounts of α4CFP and β2YFP subunits were coexpressed with various concentrations of RIC-3.
The ratio of RIC-3 to α4CFP β2YFP nAChR cDNAs was varied to 0:1 , 0.02:1, 0.1:1, 1:1, and 5:1. (A) Quantification of FRET efficiencies between
α4CFP and β2YFP subunits showed no significant change over various concentrations of RIC-3 up to 1:1 concentration (p = 0.08, one-way
ANOVA). (B) Quantification of mean α4CFP fluorescence per cell showed a significant progressive increase with rising concentrations of RIC-3
(p < 0.0001, Kruskal-Wallis rank sum test). (C) The mean β2YFP fluorescence intensity per cell showed a significant increase with increasing
concentrations of RIC-3 (p < 0.0001, Kruskal-Wallis rank sum test). (B, C) However, high RIC-3 concentrations at 5:1 reduced both α4CFP and β2YFP
fluorescence intensities closer to baseline values. Significant difference levels comparing groups of RIC-3 coexpressing cells relative to no RIC-3
controls: * p = 0.02, ** p = 0.002, *** p < 0.0001, NS p > 0.05, Wilcoxon rank sum test post-hoc pair wise analyses.
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increasing α4 subunit protein levels as measured by
α4CFP fluorescence (p < 0.0001, Kruskal-Wallis rank
sum test) (Figure 4B). There was a step-wise increase in
α4CFP fluorescence from 0:1 to 1:1 ratio of RIC-3 to
nAChR, with a decrease closer to baseline levels with
RIC-3 expression at 5:1. Similarly, there was a significant
increase in β2YFP fluorescence with increasing concen-
trations of RIC-3 (p < 0.0001, Kruskal-Wallis rank sum
test) (Figure 4C).
Therefore, the effect of RIC-3 on α4β2 receptors is
vastly different than α7 nAChRs. RIC-3 does not affect
subunit assembly between α4 and β2 but upregulates α4
and β2 protein expression.
RIC-3 interacts with α7 and β2 subunits
We have shown that RIC-3 increases assembly of α7 but
not α4β2 nAChRs and that high concentrations of RIC-3at 5:1 can disrupt α7 and α4β2 assembly. Using FRET
measurements between a fluorescently tagged RIC-3
(CFP-RIC-3) and one of the fluorescently tagged nico-
tinic receptors we examined whether RIC-3 selectively
interacts with α7 receptors.
In experiments where a 1:1 molar ratio of CFP-RIC-3
was cotransfected with α7-Venus in HEK293T cells there
was a high FRET efficiency (26 ± 7%) (Figure 5). In con-
trast, when a high molar ratio of CFP-RIC-3 was
cotransfected with α7-Venus at 5:1, FRET efficiency sig-
nificantly declined to 4.7 ± 0.8% (p = 0.007, Welch two
sample t-test).
We examined for interactions between RIC-3 and β2
by transfecting cells with CFP-RIC-3, β2YFP and
nonfluorescent α4 subunit cDNA. In contrast to our re-
sults for α7, we detected very little FRET at either 1:1
(4.6 ± 1.9%) or 5:1 (4.2 ± 0.4%) CFP-RIC-3 to β2YFP nic-
otinic subunit ratios. We then tried two lower
Figure 5 FRET efficiency measurements show that RIC-3 interacts with α7 and β2 nicotinic subunits. (A-I) Pixel based FRET was used to
monitor assembly between CFP-RIC-3 and a fluorescently tagged nicotinic receptor subunit (either α7-Venus or β2YFP). (J) Summary data
showing significantly higher levels of FRET efficiency between CFP-RIC-3 and α7-Venus at 1:1 ratio as compared to 5:1 ratio (p = 0.007, Welch two
sample t-test). There was significantly greater FRET efficiency between CFP-RIC-3 and β2YFP at 0.2:1 (p = 0.003, Wilcoxon signed rank test post-hoc
analysis) and 0.5:1 (p < 0.0001, Wilcoxon signed rank test post-hoc analysis) ratios as compared to 5:1 ratio. Also there was significantly greater
FRET efficiency between CFP-RIC-3 and β2YFP at 0.2:1 (p = 0.009, Wilcoxon signed rank test post-hoc analysis) and 0.5:1 (p = 0.002, Wilcoxon
signed rank test post-hoc analysis) ratios as compared to 1:1 ratio. No significant (NS) FRET efficiency could be detected between CFP-RIC-3 and
α4YFP (p = 0.55, Kruskal-Wallis rank sum test) even though there was a similar trend as β2YFP. Therefore, equimolar RIC-3 interacts with α7 while
RIC-3 optimally interacts with β2 at a 0.5:1 molar ratio.
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ratios and found significant increases in FRET signal at
0.5:1 (10.7 ± 1.0%) (p < 0.0001, Wilcoxon rank sum test
post-hoc analysis) and 0.2:1 (10.8 ± 1.4%) (p = 0.003,
Wilcoxon rank sum test post-hoc analysis) (p = 0.0002,
Kruskal-Wallis rank sum test) as compared to 5:1. We also
found significant increases in FRET at 0.5:1 (p = 0.002,
Wilcoxon rank sum test post-hoc analysis) and 0.2:1
(p = 0.009, Wilcoxon rank sum test post-hoc analysis)
(p = 0.0002, Kruskal-Wallis rank sum test) in relation
to 1:1. In an analogous set of experiments with cells
cotransfected with CFP-RIC-3, α4YFP and nonfluorescent
β2 subunit cDNA we found a similar trend as with β2YFP
with FRET efficiencies increasing as we lowered the CFP-
RIC-3 to α4YFP ratio to 0.5:1 (9.4 ± 5.2%) or below (8.0 ±
3.1%, at 0.2:1), while there was very low FRET efficiency at
1:1 (1.5 ± 2.3%) and 5:1 (3.0 ± 1.4%). However, the changes
in FRET efficiencies were not significant (p = 0.55, Kruskal-
Wallis rank sum test).
These results show that RIC-3 associates with α7 nico-
tinic receptor subunits and β2 subunits. Interestingly,
RIC-3 interacts with α7 and β2 subunits at different rela-
tive cDNA ratios – 1:1 with α7 and 0.5:1 with β2.
Acute nicotine upregulates FRET between α4 and β2
subunits but RIC-3 prevents nicotine-induced
upregulation
Chronic nicotine exposure is known to upregulate high af-
finity nicotinic receptors whether performed in vivo in ro-
dents or in vitro in cell lines [1,36,37]. The mechanism for
receptor upregulation is unclear but many have been pro-
posed [1-4,9,10]. We previously reported increased FRET
efficiency between α4YFP and β2CFP nicotinic subunits
and increased protein levels of α4YFP and β2CFP subunits
in cultured midbrain neurons following 24 hrs of chronic
nicotine exposure [1]. In that study we proposed that en-
hanced receptor assembly may be one contributing mech-
anism of nicotinic receptor upregulation. However, an
equally likely mechanism of increased FRET with 24 hrs
of nicotine could involve a decreased degradation of re-
ceptors. Nevertheless, both mechanisms are not mutually
exclusive and both can potentially contribute to receptor
upregulation. Given that the turnover rate for α4β2
nAChRs is relatively slow (half life = 7–13 hrs, [2,9,10,38]),
examining the effects of nicotine at a very acute time point
(30 min nicotine exposure) would preclude the effects of
degradation of the subunits so that any FRET increase, if
any, can be attributed to stimulation of assembly of α4β2
nAChRs. Therefore, we examined whether nicotine expos-
ure truly stimulates receptor assembly by looking at a very
acute time point, 30 min of nicotine exposure.
We first examined changes in FRET efficiencies be-
tween α4CFP and β2YFP subunits in the absence of
RIC-3 at various doses of nicotine for 30 min exposure.We were surprised to observe a robust increase in FRET
efficiency between α4CFP and β2YFP as early as 30 min
post nicotine exposure (Figure 6A). This effect was sig-
nificant (p = 0.002, Kruskal-Wallis rank sum test) and
dose-dependent, with significant increases in FRET effi-
ciency at 1 μM (27 ± 3%, p = 0.03, Wilcoxon rank sum
test post-hoc analysis) and 10 μM nicotine (33 ± 2%,
p = 0.002, Wilcoxon rank sum test post-hoc analysis) as
compared to control (18 ± 3%).
In our previous experiments (Figure 4B, C), we discov-
ered that RIC-3 can increase α4CFP and β2YFP protein ex-
pression. Therefore, to examine whether RIC-3 could
potentially augment the nicotine-mediated FRET increase,
we performed the same experiments but additionally
coexpressed RIC-3 with α4CFP and β2YFP nAChR sub-
units. We used the 1:1 ratio of RIC-3 to nAChR subunit be-
cause this concentration resulted in a significant and robust
upregulation of α4 protein and also was the concentration
which maximally increased α7 assembly. Interestingly,
there was no change in FRET efficiency as RIC-3 prevented
nicotine-mediated upregulation of α4CFP β2YFP receptor
assembly at all concentrations of nicotine tested (Figure 6A).
However, regardless of the absence or presence of nicotine
at various concentrations, RIC-3 was still effective at signifi-
cantly increasing α4 and β2 protein expression (p < 0.0001,
RIC-3 factor, two-way ANOVA; for both α4 and β2) as
measured from α4CFP and β2YFP fluorescence (Figure 6B,
C). However, 30 min of nicotine at all concentrations was
ineffective at altering α4CFP or β2YFP protein levels as
measured by fluorescence intensity whether RIC-3 was
present or not (Figure 6B, C).
Therefore, coexpression of the heteromeric α4β2 nico-
tinic receptors with RIC-3 inhibits the effect of nicotine
on upregulating FRET between receptor subunits. How-
ever, RIC-3 specifically upregulates α4 and β2 subunit
protein levels regardless of the presence of nicotine.
Anti-HA epitope receptor binding confirms that RIC-3 but
not 30 min nicotine upregulates α4 and β2 protein
We showed that 30 min of nicotine incubation increased
FRET efficiency between α4CFP and β2YFP (Figure 6A),
which we interpret as increased subunit assembly. How-
ever, one possibility is that the changes in FRET may re-
flect a conformational change in the receptors due to
decreased distance between subunits during channel gat-
ing with nicotine and may not have anything to do with
increased receptor assembly. To rule out this possibility,
we performed a set of FRET experiments to examine
whether nicotine can cause a conformational change to
the receptor that is sensed by our FRET assay (Figure 7A).
This should occur less than a second following nicotine
binding to the receptor and result in a conformational
change. Therefore, we performed time lapsed FRET mea-
surements between α4CFP β2YFP to monitor FRET
Figure 6 Effect of acute nicotine treatment on FRET efficiency and protein expression of α4CFP and β2YFP subunits in the presence or
absence of RIC-3. Equimolar amounts of α4CFP and β2YFP cDNA were transfected either with (1:1 ratio of RIC-3 to nAChR subunit) or without
RIC-3. Cells were incubated in various nicotine concentrations (0, 0.1, 1 and 10 μM) at 37°C 30 min before imaging. (A) In the absence of RIC-3
there was a significant progressive increase in FRET efficiency between α4CFP and β2YFP subunits, signifying receptor assembly, at all
concentrations of nicotine (p = 0.002, Kruskal-Wallis rank sum test). With RIC-3 there was no change in FRET efficiency between α4CFP and β2YFP
subunits with increasing concentrations of nicotine. Significant difference levels comparing groups of nicotine concentrations relative to no
nicotine control: *, p = 0.03, **, p = 0.002 (Wilcoxon rank sum tests). Quantification of mean α4CFP (B) and β2YFP (C) fluorescence intensities per
cell showed no change with increasing nicotine concentrations whether RIC-3 (at 1:1 ratio) was present or absent. However, the mean α4CFP and
β2YFP fluorescence intensities with RIC-3 was significantly greater than without RIC-3 at all nicotine concentrations (p < 0.0001, RIC-3 factor,
two-way ANOVA; for both α4CFP and β2YFP subunits). For pairwise comparison of α4CFP and β2YFP fluorescence between no RIC-3 and RIC-3
coexpression at each nicotine concentration significance levels are reported as p values (post-hoc pairwise Tukey’s HSD tests).
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applied 10 μM nicotine, which should be long enough to
monitor any FRET changes due to conformational changes
of the receptors as they bind to nicotine but too brief to
monitor any receptor assembly. Accordingly, we measured
baseline FRET efficiencies, then bath applied 10 μM nico-
tine and then monitored FRET at 1 and 3 min during
nicotine application. Our results show that at a time scale
of 3 min there is no significant FRET change between
α4CFP and β2YFP (p = 0.88, one-way repeated measures
ANOVA, n = 12) (Figure 7A). These results show that the
FRET measurements that we undertook are not compli-
cated by FRET changes due to receptor conformational
changes at 3 min nicotine exposure. Furthermore, we do
witness a robust FRET increase at 30 min with nicotine
incubation (Figure 6A). Together, these results support ourhypothesis that nicotine is enhancing receptor assembly
(over 30 min of nicotine exposure).
Although in a previous study we have shown that
following 24 hrs of nicotine incubation there is
upregulation of α4 and β2 subunit protein expression
[1], in this study we could not detect changes in protein
expression of α4CFP and β2YFP after 30 min of nicotine
exposure as measured by fluorescence from the fluores-
cent protein tags. To verify these results we repeated
analogous experiments using a concentration of nicotine
(10 μM) that resulted in maximal nicotine-induced
upregulation of receptor assembly and examined whether
there was an upregulation in α4 and β2 subunit protein
expression using anti-HA antibody labelling of the
nicotinic receptor subunits. We used either a combin-
ation of α4CFP β2YFP or α4YFP β2CFP transfected
Figure 7 Anti-HA epitope antibody binding confirms no change in nAChR protein with 30 min nicotine and no change in nAChR
conformation within 3 min of nicotine. (A) Equimolar amounts of α4CFP and β2YFP cDNA were transfected in HEK293T cells and time lapse
imaging of FRET was performed at 30°C. Cells were imaged for FRET at 1 and 3 min before and 1 and 3 min during 10 μM nicotine incubation.
There was no significant change (p = 0.88, one-way repeated measures ANOVA, n = 12) in FRET efficiency between nicotinic receptor subunits
with bath applied nicotine during the 3 min nicotine incubation. (B) 30 min application of 10 μM nicotine did not alter anti-HA epitope antibody
binding of HA epitope tagged α4 (α4-HA) and β2 (β2-HA) subunits expressed in HEK293T cells. (C) RIC-3 coexpression with α4-HA and β2-HA
subunits resulted in significantly enhanced levels of anti-HA antibody labelling of α4-HA (p < 0.0001, Wilcoxon rank sum test) and β2-HA
(p < 0.0001, Wilcoxon rank sum test) subunits as compared to cells not coexpressing RIC-3.
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immediately upstream of the fluorescent protein and were
identified in Figure 7 as β2-HA and α4-HA, respectively.
Similar to our previous results (Figure 6B, C), 10 μM nico-
tine for 30 min did not significantly alter α4 (p = 0.17,
Wilcoxon rank sum test) nor β2 (p = 0.67, Wilcoxon rank
sum test) subunit protein levels (Figure 7B). However, our
anti-HA binding assay was able to detect significant
increases of α4 (p < 0.0001, Wilcoxon rank sum test)
and β2 (p < 0.0001, Wilcoxon rank sum test) subunit
proteins with RIC-3 cotransfection (Figure 7C).
These set of data using a second experimental ap-
proach are consistent with our previous data and sup-
port that 30 min of nicotine exposure does not result in
any detectable change in α4 and β2 subunit protein ex-
pression. However, with over two days of coexpression
with RIC-3 results in an augmentation of α4 and β2 pro-
tein levels. Furthermore, the fact that we see nicotine in-
duced increased in FRET over 30 min and not within
3 min supports that our FRET increases reflect receptorassembly and rules out FRET changes due to nicotine in-
duced conformational changes of the receptor as a result
of channel gating. However, Govind et al. [38] showed
that there are two time courses of nAChR upregulation.
Their results showed that the rapid upregulation (time
constant = 1.1 hrs) component is due to receptor con-
formational changes. Thus, we cannot rule out that the
FRET changes between α4β2 with 30 min nicotine may
be contributed by receptor conformational changes inde-
pendent of channel gating.
Acute nicotine does not upregulate assembly of α7
receptors in the presence or absence of RIC-3
It has been proposed that nicotine acts as a pharmaco-
logical chaperone to enhance assembly of α4β2 nicotinic
receptors [9]. To determine if agonist binding can also
enhance assembly of α7 subunits, the effect of acute
(30 min) nicotine treatment on receptor assembly was
tested, first in the absence of the chaperone, RIC-3. We
found that varying the concentrations of nicotine from
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tween α7-Cerulean and α7-Venus in the absence of RIC-
3 (p = 0.12, Kruskal-Wallis rank sum test) indicating that
acute nicotine was unable to upregulate α7 receptor as-
sembly (Figure 8).
We surmised that the lack of effect of nicotine on α7
may have been due to the fact that there were no surface
receptors to begin with in the absence of RIC-3 and that
there would need to be a basal level of functional surface
receptors for acute nicotine to have its effect. Hence, we
repeated the same experiments but this time we
coexpressed RIC-3 in a 1:1 ratio with α7-Cerulean and
α7-Venus in order to examine the effect of acute nico-
tine in the presence of assembled α7 receptors. Similarly,
following 30 min nicotine incubation we witnessed no
change in FRET efficiency between α7-Cerulean and α7-
Venus subunits over all concentrations of nicotine tested
vs control (Figure 8) (p = 0.4, one-way ANOVA). How-
ever, at all nicotine concentrations α7 receptors had sig-
nificantly higher FRET efficiencies with RIC-3 as
compared to without RIC-3 (p = 0.001, RIC-3 factor,
two-way ANOVA) (Figure 8), suggesting that RIC-3 can
still enhance receptor assembly independent of the pres-
ence of nicotine. Notably, nicotine had no effect on α7
subunit expression as there was no significant change inFigure 8 Effect of acute nicotine treatment on FRET efficiency
of α7-Cerulean and α7-Venus subunits in the presence or
absence of RIC-3. Equimolar amounts of α7-Venus and α7-Cerulean
were transfected either without RIC-3 or with RIC-3 at a 1:1 ratio to
the nAChR subunit. Cells were incubated at various concentrations
of nicotine (0, 0.1, 1 and 10 μM) at 37°C for 30 min prior to imaging.
Whether RIC-3 was present or absent, there was no change in FRET
efficiency between α7-Venus and α7-Cerulean subunits over
increasing concentrations of nicotine (30 min) (p = 0.3, and p = 0.12,
Kruskal-Wallis rank sum tests, respectively). However, the FRET
efficiency between α7-Venus and α7-Cerulean was signficantly
greater in the presence than the absence of RIC-3 at each of the
nicotine concentrations (*, p < 0.05, **, p < 0.01, Wilcoxon rank sum
test or t-test).mean α7-Cerulean and α7-Venus fluorescence per cell at
all nicotine doses tested, whether RIC-3 was present or
not (data not shown).
Therefore, acute nicotine treatment does not upregulate
assembly of α7 receptors, and RIC-3 co-transfection is in-
sufficient to promote the sensitivity of the receptor to
upregulation by the agonist.
Discussion
In the present study we examined the role of RIC-3
chaperone protein on the assembly of α7 and α4β2
nAChRs and the effect of RIC-3 in modulating nicotine
mediated upregulation of α4β2 and α7 receptor assem-
bly. Using FRET analysis between fluorescently tagged
α7 subunits we found that low RIC-3 concentrations in-
creased assembly of α7 receptors in a dose-dependent
manner, but had no effect on receptor assembly at high
RIC-3 concentrations (5:1 ratio of RIC-3 to α7). This
was corroborated with Fl-Bgt labeling, which addition-
ally showed that RIC-3 stimulated forward trafficking of
the receptor to the cell surface at all concentrations. In
contrast, the chaperone did not affect assembly of the
heteromeric α4β2 receptors, suggesting that the effect of
RIC-3 on assembly is specific to the homomeric α7
receptor. However, RIC-3 specifically upregulated α4
and β2 subunit protein expression in a dose-dependent
manner, but had no effect on α7 subunit protein expres-
sion. We examined the effects of acute nicotine exposure
and found that 30 min was sufficient to stimulate
upregulation of FRET between α4 and β2 receptor subunits
in a nicotine dose-dependent manner (0.1 – 10 μM) in the
absence of RIC-3. Interestingly the presence of RIC-3
prevented nicotine-mediated upregulation of FRET between
α4 and β2 at all nicotine concentrations. Acute nico-
tine exposure (30 min) was unable to upregulate α7
nicotinic receptors whether or not RIC-3 was present.
At this short time frame (30 min) of nicotine expos-
ure, there was expectantly no detectable change in
α4, β2 and α7 protein expression.
RIC-3 increases assembly and surface expression of α7
receptors
FRET is a spectroscopic technique that can be used to
measure receptor assembly or receptor subunit stoichi-
ometry [1,27,28,39]. The marked enhancement in FRET
efficiencies between the fluorescent α7 subunits with in-
creasing amounts of RIC-3 plasmid (Figure 1) supports
previous studies that RIC-3 acts as a chaperone to pro-
mote the maturation and assembly of α7 receptors
[17,22,23,35]. Assembly levels peaked when the RIC-3
chaperone and the receptor were transfected at equimo-
lar ratios suggesting that the stoichiometry for efficient
receptor assembly is one RIC-3 molecule for every α7
subunit [20].
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control values at a 5:1 transfection ratio (Figure 1),
suggesting that at high expression levels RIC-3 loses its
ability to mediate receptor assembly likely due to RIC-3
self aggregation [22]. At sufficiently high chaperone con-
centrations in the ER, RIC-3 monomers may self-assemble,
likely via their coiled-coil domains [40], leading to the
formation of large aggregates. Such conditions would
sterically hinder the ability of RIC-3 to effectively bring
α7 subunits into close proximity, preventing assembly
and retaining the subunits in the ER. This is supported by
our FRET experiments between CFP-RIC-3 and α7-Venus,
which showed a significantly high FRET efficiency when
they were coexpressed at 1:1 ratio and a negligibly low
FRET efficiency when expressed at 5:1 (Figure 5). We
think that at high RIC-3 concentration (5:1) RIC-3 does
not lose its ability to interact with α7. A likely possibility
is that the FRET signal is diluted at 5:1. At 5:1 CFP-RIC-3
to α7-Venus, RIC-3 is in excess. For every RIC-3 bound
to α7-Venus there are four molecules of RIC-3 that are
unbound. Because FRET signal relies on the interaction
of a donor fluorescent molecule to its acceptor, we
would predict that the 5:1 ratio should have a FRET
efficiency that is 20% of that at 1:1 ratio because of
excess unbound donors. This is what we observe as at
1:1 the FRET efficiency is 26 ± 7% and at 5:1 the FRET
efficiency is 4.7 ± 0.8%, which is 18% of 1:1 and is
within the standard error range.
Results from α-Bgt labelling experiments were used to
support the FRET measurements of receptor assembly.
The Fl-Bgt signal was almost undetectable in the ab-
sence of RIC-3, but the total number of Fl-Bgt binding
sites increased significantly in the presence of the
chaperone (Figures 2, 3). In agreement to the initial
FRET measurements (Figure 1J), this result further dem-
onstrates that RIC-3 can increase assembly of α7 sub-
units. It was important, however, to confirm that the
increase in the total number of α-Bgt binding sites was
due to assembly of already expressed subunits rather
than an increase in protein levels. In agreement with
previous studies [22,41] the protein levels of α7 did not
change significantly upon cotransfection with the
chaperone (Figure 3). Thus, the effect of RIC-3 on sub-
unit assembly is entirely independent on expression
levels of individual subunits. It was found that the num-
ber of α-Bgt binding sites increased more extensively on
the surface than within the cell upon addition of RIC-3
(Figure 3). Alexander and colleagues [22] have observed
a similar trend, with a 5-fold increase in whole-cell
levels, and a 40-fold increase in surface levels of receptor
upon cotransfection of the chaperone. Thus, RIC-3 has
an additional role of transporting the receptor to the
surface. In fact, since proper assembly is a pre-requisite
for exit of the receptor from the ER [42] the sole abilityof RIC-3 to enhance receptor assembly could promote
its release from the ER and procession along the
secretory pathway.
Interestingly, the highest level of RIC-3 transfection (5:1
ratio to α7) dropped surface expression levels relative to
the peak values, although these levels were still signifi-
cantly higher than control. Again, this data suggests that
RIC-3 can partly lose its function when expressed at high
levels, possibly by forming self-aggregates in the ER that
hinder α7 export to the surface. In contrast, whole cell
levels of receptors peaked at this transfection ratio, which
suggests that although the aggregates may hinder receptor
trafficking, they have no deleterious effects on its assem-
bly. Our Fl-Bgt data are consistent with the results of the
study of Alexander and colleagues [22]. However, the α-
Bgt labelling data differ somewhat to our FRET results,
which indicate a loss of chaperone-mediated assembly at
the highest level of RIC-3 (Figure 1J). Alexander and col-
leagues [22] observed the formation of aggregates
containing both RIC-3 and α7 in structures they described
as autophagosomes in high expressing RIC-3 cells. At high
RIC-3 concentrations α7 did not traffic to the cell surface
but was retained in the ER and accumulated in aggregates.
Another study showed that autophagosomes are respon-
sible for degradation of AMPA receptors [43]. Perhaps
there could be degradation of the excess assembled nico-
tinic receptors in the autophagosomes but the overall
number of receptors are still elevated. This would be con-
sistent with an increase in total α-Bgt binding sites that we
observed in Figure 3A. Since FRET measures the propor-
tion, not the total number, of assembled subunits and high
RIC-3 is possibly stimulating the degradation of excess as-
sembled nicotinic receptors, a change in proportion would
decrease the overall FRET signal closer to control values,
which is what we observe at 5:1 RIC-3 to α7 (Figure 1J),
regardless of the net increase in total assembled receptors,
which is what we observed with α-Bgt labelling (Figure 3A).
Interestingly, we observed this similar trend with α4β2,
where at 5:1 RIC-3 to α4β2 there was a decrease in
FRET efficiency between α4 and β2 subunits (Figure 4A).
At 5:1 RIC-3, the reason that there is no change in α7
subunit protein levels is that there may be an increased
production of unassembled α7 protein subunits that
balances the degradation of α7 receptors, which will
further decrease FRET efficiency.
Effects of RIC-3 on α4β2 receptors
FRET between α4 and β2 constructs does not change sig-
nificantly when RIC-3 is coexpressed with the heteromeric
subunits (Figure 4A) at all concentrations of RIC-3 except
for the high 5:1 concentration, which attenuated FRET sig-
nal. This suggests that the ability of RIC-3 to enhance re-
ceptor assembly is specific to α7. Interestingly, using FRET
measurements between CFP-RIC-3 and fluorescently
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acts with β2YFP but at a lower cDNA ratio than with α7-
Venus. Through FRET we observed that RIC-3 interacts
with β2YFP at a 0.5:1 ratio while with α7-Venus RIC-3
interacts at a 1:1 ratio (Figure 5). We observed a similar
trend of FRET efficiencies between CFP-RIC-3 and α4YFP
over various concentrations of CFP-RIC-3 but the results
did not reach significance. These results are supported by a
previous study [17], which showed that both α4 and β2
nAChR subunits interact with RIC-3 using immunopre-
cipitation experiments. Although a lower cDNA ratio of
RIC-3 was required to interact with β2 as compared to
α7, future experiments must be performed to determine
whether the stoichiometry of interaction at the protein
level is actually lower for β2.
Although we did not find that RIC-3 stimulated any
changes in assembly between α4 and β2 subunits, we did
find that RIC-3 specifically increased α4 and β2 subunit
protein expression (Figures 4 and 6), which would likely
result in increased nicotinic responses given that the
proportion of assembled receptors would remain un-
altered but the total number of assembled receptors
would increase. This is supported by the same previous
study which showed that RIC-3 steadily increases func-
tional expression of the α4β2 receptors in transfected
mammalian cells [17].
Furthermore, the ability of the chaperone RIC-3 to in-
crease α4 and β2 subunit protein expression makes
sense, given that the association of other chaperone pro-
teins such as 14-3-3 and phosphorylation of α4 results
in increased expression of α4β2 receptors as determined
by cytisine binding and Western blots [44]. In comparison
to other subunits, α4 has the largest M3-M4 cytoplasmic
loop (~260 aa) with many post-translational modifica-
tion sites that can potentially regulate protein expression
and receptor turnover [1,44,45]. It is conceivable that when
RIC-3 binds to α4β2 receptors RIC-3 may act like 14-3-3
to upregulate receptor protein expression levels [45]
possibly by inhibiting signals targeting for degradation.
In fact, β2 subunits have a strong ER retention motif
and by binding to RIC-3, this may stimulate forward
trafficking of α4β2 receptors and thus, protect them
from ER associated degradation [22]. However, further
studies are required to reveal the exact mechanism by
which RIC-3 modulates protein levels of these sub-
units. We expect that the total number of assembled
receptors would increase because RIC-3 maintains the
same proportion of assembled α4β2 receptors as mea-
sured by no change in FRET while the protein levels of
both subunits increase.
The fact that RIC-3 does not influence assembly of α4β2
receptors is expected. In fact, maturation of the heteromer
may rely on other chaperones, such as Calnexin, Bi P,
UNC-50, and 14-3-3 [45-47]. Furthermore, unlike α7,heteromeric α4β2 receptors can express at high levels in a
variety of systems in the absence of RIC-3 [17] suggesting
that the chaperone is not essential for the assembly of
α4β2. The ability of RIC-3 to have differing effects on spe-
cific receptor subtypes may have physiological implica-
tions. α7 homomers are only observed in regions of the
brain that also express RIC-3 [48]. By regulating the
tissue-dependent expression of RIC-3, the nervous system
can directly and specifically control the regional distribu-
tion of α7 expression in the brain, without altering the ex-
pression levels of other receptors.
RIC-3 modulates nicotine-induced receptor upregulation
The majority of studies on nicotine-mediated nAChR
upregulation have focused on the chronic effects of ago-
nists or antagonists, mainly on time frames of 24 hrs to a
few days in cell and neuronal culture [1-4,9-11], 10 to 30
days for chronic nicotine exposure in rodents [6,7,36,49]
and many years in smokers’ brains [8,50]. Multiple parallel
mechanisms of nicotine-induced nicotinic receptor upre-
gulation are likely to exist [38]. Harkness and Millar [51]
showed that α4β2 receptors increase in total and surface
epibatidine binding after 24 hrs of nicotine exposure but
there was no change in overall protein levels of α4 or β2.
Post-trancriptional or post-translational mechanisms must
be involved in receptor upregulation since there is no
change in mRNA transcript for both α4 or β2 [7]. A plaus-
ible explanation of increased epibatidine binding with no
subunit protein change could be increased receptor as-
sembly of an already existing pool of unassembled recep-
tor subunits. We previously found that 24 hrs of nicotine
exposure increased FRET between α4 and β2 receptors in-
dicating that there were more assembled receptors [1].
We proposed that 24 hrs of nicotine stimulates assembly
of the receptors. However, an equally likely scenario is that
24 hrs of nicotine protects the receptors from degradation
[52]. The half-life of α4β2 receptors is reported to be 7–13
hrs [2,9,10]. However, our results show increased FRET ef-
ficiency between α4 and β2 subunits after 30 min of incu-
bation with nicotine (Figure 6A). This finding supports
that nicotine is stimulating assembly of receptors since a
decreased degradation rate cannot account for the alter-
ation in receptor numbers at this short time frame of 30
min. The effect of nicotine decreasing the degradation rate
of receptor protein would require hrs to be detectable and
is also likely to contribute to receptor upregulation at the
longer time scale of hrs [38].
However, one potential caveat in our FRET experi-
ments between α4CFP and β2YFP is that nicotine would
cause conformational changes due to gating of the α4β2
channels, which would result in changes in FRET. When
we applied nicotine in the dish we witnessed no alter-
ations in FRET at 1 and 3 min during nicotine applica-
tion and therefore ruling out this possibility (Figure 7A).
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loops, a region not known for gating, FRET changes
were not expected. This set of control experiments sup-
port our hypothesis that 30 min of nicotine is stimulat-
ing assembly. However, Govind and colleagues [38]
showed that nAChR upregulation has two different
mechanisms occurring at different rates. Their results
support that the fast transient (τ = 1.1 hrs) nAChR
upregulation corresponds to nAChR conformational
changes. Our FRET experiments cannot rule out the
possibility that our nicotine-induced increase in FRET
between α4β2 may be contributed by receptor conform-
ational changes.
Our results also showed that 30 min of nicotine stimu-
lated increased FRET between α4 and β2 with no change
in both α4 or β2 subunit protein expression (Figures 6B,
C, 7B). However, at longer time scales we found that 24
hrs increased α4 and β2 protein expression in cultured
midbrain neurons and 10 days of chronic nicotine expos-
ure in mice increases α4 subunit protein expression in the
CNS [6,53]. This is likely due to the fact that mRNA tran-
scription, followed by protein translation would require
several hours to manifest, and thus cannot occur within
the time frame of the present experiments.
Surprisingly, when we coexpressed RIC-3 with α4β2
receptors, 30 min nicotine was unable to upregulate re-
ceptor assembly (Figure 6A), suggesting that RIC-3
prevented nicotine-induced receptor upregulation of as-
sembly. This data opens the possibility that RIC-3 can
modulate α4β2 receptor upregulation in specific neurons
in the CNS by the selective co-expression of RIC-3. Not-
ably, the phenomenon of nicotine-induced receptor
upregulation occurs in many but not all regions of the
brain [5-7]. We have shown previously that chronic
nicotine can cause selective upregulation in specific sub-
types of neurons in particular brain regions [6]. Specific-
ally in the VTA and SN α4 receptors are upregulated in
GABAergic neurons but not dopaminergic neurons. We
propose a novel mechanism whereby nicotine-mediated
receptor upregulation can be prevented by the effects of
the RIC-3 chaperone protein. However, there are likely
other possibilities including the presence of other nicotinic
receptor subunits, such as α5, with α4β2 receptors can
inhibit receptor upregulation in vivo [54]. Furthermore, in
mouse brains following chronic nicotine administration
nicotine-induced nAChR upregulation occurs in many
brain regions except for specific brain regions where α4 is
highly expressed such as the medial habenula, thalamus
and dopaminergic neurons where there is no nicotine-
induced upregulation of receptors [6,7]. These reported
data may be analogous to the effect of RIC-3 preventing
nicotine-induced upregulation. A possibility is that the re-
ceptor number in both scenarios are already at a high and
saturated level so nicotine cannot further increase proteinlevels (Figures 6B, C, 7C). This hypothesis is supported
by a previous study by Wang and colleagues [55] who
showed that cells expressing α3β2 had low levels of
receptors but had robust nicotine-induced upregulation.
In contrast, cells expressing α3β4 receptors had approxi-
mately four times greater baseline receptor expression
than α3β2 but nicotine exposure was unable to upregulate
α3β4 receptors.
The fact that nicotine, at all concentrations tested, did
not induce upregulation of α7 receptor assembly is not
surprising. In general, α7 receptors are more resistant to
nicotine-induced upregulation. In cell lines, α7 receptors
require at least 1000 fold higher concentration of nicotine
(10 μM vs 10 nM) than α4β2 and α7 receptors show a
minimal amount of upregulation as compared to α4β2,
which may show several fold upregulation in cell lines
[4,11,12]. In studies on human smokers’ brains, there is
even conflicting data as to whether α7 receptors are in-
creased at all unlike α4β2, which are consistently aug-
mented in smokers’ brains [8,50,56]. Several studies have
noted increased expression of α7 receptor levels following
treatment with agonists, but these trends are only noted in
incubation periods longer than 24 hours [11-13]. Since
nicotine may primarily exert its effects on the cell surface,
it is conceivable that by increasing the surface expression
of mature receptors, RIC-3 may in turn enhance the sensi-
tivity of the receptor to the effects of the agonist. Interest-
ingly, although RIC-3 increased FRET efficiencies between
α7 subunits, nicotine treatment at all doses yielded no sig-
nificant changes in α7 assembly in the presence of the
RIC-3 chaperone (Figure 8). These sets of results suggest
that one of the mechanisms of nicotine-induced receptor
upregulation is stimulation of receptor assembly for α4β2
but not for α7 receptors.
Conclusions
These results support previous data on the role of RIC-3
in enhancing assembly and surface trafficking of α7 re-
ceptors. Additionally, this study demonstrates for the
first time that RIC-3 differentially affects assembly and
protein expression of α4β2 and α7 receptors. While
RIC-3 directly interacts with α7 subunits in a 1:1 cDNA
ratio to enhance receptor assembly without altering pro-
tein expression, RIC-3 interacts with β2 at a lower
cDNA ratio (0.5:1) but does not influence assembly be-
tween α4 and β2 subunits. Interestingly, RIC-3 causes a
selective increase in expression of α4 and β2 subunits
but prevented nicotine-induced increased FRET between
α4 and β2 subunits. Since experiments were conducted
on HEK293T cells, further investigation would be required
to examine whether similar regulation of nicotinic re-
ceptor assembly and expression with RIC-3 and nico-
tine would be recapitulated in subtype specific neurons
in the brain. Our results suggest that RIC-3 chaperones
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nicotine-mediated α4β2 receptor upregulation of receptor
assembly.
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